Assertio

Assertio Holdings, Inc. is a specialty pharmaceutical company based in Lake Forest, Illinois, focused on developing and commercializing products for pain management and central nervous system conditions. Founded in 1995, the company markets several FDA-approved products, including CAMBIA, a non-steroidal anti-inflammatory drug for treating migraines; Zipsor, which provides relief for mild to moderate acute pain; and Gralise, a once-daily gabapentin formulation for managing postherpetic neuralgia. Assertio also offers NUCYNTA ER and NUCYNTA IR, extended-release and immediate-release formulations of tapentadol, respectively, for neuropathic pain and moderate to severe acute pain. The company has established collaborations, including a licensing agreement with Ironwood Pharmaceuticals, further enhancing its position in the specialty pharmaceutical market.